Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2825 + GemOx in Relapsed/Refractory DLBCL
NCT06854445Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tqb2825 in diffuse large B-cell lymphoma (DLBCL), sponsored by Chia Tai Tianqing. Started Mar 2025; status: recruiting.
02
Drugs
tqb2825
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06854445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854445.